|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||170.13 - 171.44|
|52 Week Range||128.91 - 171.44|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.44%|
On July 27, 2017, Baxter International (BAX) completed the acquisition of Claris Injectables, which is expected to help expand and strengthen Baxter’s core capabilities.
On September 7, 2017, BAX stock closed at $62.84 per share. It has a 50-day moving average of $61.15 and a 200-day moving average of $57.14.
Edwards Lifesciences (EW), a leader in the artificial heart valve market, has been expanding rapidly amid its new product launches and innovative product pipeline.
Boston Scientific (BSX) currently has a global market opportunity of $40.0 billion, which is expected to grow to $50.0 billion by fiscal 2020.
Zimmer Biomet closed trading at price of $113.1 on August 30. The stock has a 50-day moving average of $119.95 and a 200-day moving average of $120.95.
On August 31, Stryker (SYK) closed trading at a closing price of $139.3. It has a 50-day moving average of $144.7 and a 200-day moving average of $137.5.
With the spin-off of its Imaging Components business, Varian Medical Systems (VAR) is now more aligned with its core capabilities. In this series, we'll discuss the company's dynamics after the Varex spin-off....
Analysts estimate that Intuitive Surgical will post 2Q17 EPS (earnings per share) of ~$4.76. In 1Q17, Intuitive Surgical exceeded analysts’ diluted EPS estimate of $4.67.
BD (BDX) closed trading at $195.3 on July 6, 2017, ahead of its 50-day moving average of $191.3 and its 200-day moving average of $181.9.
Varian Medical Systems (VAR) was trading at $102.7 on June 29, 2017. It has a 50-day moving average of $100.4 and a 200-day moving average of $88.8.
The lowest 12-month target price for Varian Medical Systems stands at $75, while the company’s highest 12-month target price is $99.
On June 13, 2017, Zimmer Biomet (ZBH) announced that the FDA warning letter issued in June 2015 relating to its Zhejiang manufacturing facility in China has been closed.
Ximmer Biomet (ZBH) has risen 2.1% since its 1Q17 earnings release on April 27, 2017. The results exceeded analysts’ estimates, but ZBH lowered its 2017 guidance.
Keith Bliss of Cuttone and Company joins Yahoo Finance's Alexis Christoforous from the floor of the New York Stock Exchange to discuss what investors should be focusing on after the latest North Korean headline risk failed to spook the markets.
Novartis got government approval for a new cancer therapy. The treatment will cost a staggering $475,000, and it will help children and young adults with a certain type of Leukemia. Yahoo Finance's Seana Smith, Nicole Smith and Rick Newman react to what Wall Street is saying about the drug.